AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05405946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation Therapy
Description: Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials.
Study NCT05405946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
Study NCT05405946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
Study NCT01322490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Study NCT01322490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Study NCT01322490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study NCT01322490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF Placebo
Study NCT01322490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GM-CSF Placebo
Study NCT01322490 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PROSTVAC V/F Placebo
Study NCT04768101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-PIB
Description: \[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
Study NCT01661101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 110 mg taken twice daily
Study NCT01661101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dabigatran)
Description: Dabigatran placebo taken twice daily
Study NCT01661101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 mg capsule taken once daily
Study NCT01661101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Omeprazole)
Description: Omeprazole placebo taken once daily
Study NCT01069510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Spironolactone 25 mg daily for 12 months
Study NCT01069510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 12 months
Study NCT04042688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular administration of tranexamic acid
Description: Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
Study NCT04404517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Monoclonal antibody used in IBD treatment
Study NCT04214561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Each of the patients will undergo polysomnography
Study NCT02683928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBR 830
Study NCT02683928 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexter ketamine
Description: multimodal anesthesia without opioids ketamine as induction drug
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: continuous infusion intravenous
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Hydrochloride
Description: intravenous
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Hydrochloride
Description: clonidine intravenous pre induction
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: premedication
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: premedication
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane Volatile Liquid
Description: maintenance of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Volatile Liquid
Description: maintenance of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Injectable Solution
Description: induction of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injectable Solution
Description: induction of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: induction of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 % Injectable Suspension
Description: induction of general anesthesia
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-21-Sulfobenzoate, Sodium Salt
Description: at the end of the procedure 4mg IV
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone-21-Sulfobenzoate, Sodium Salt
Description: at the end of the procedure 4mg IV
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine Hydrochloride
Description: at the end of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine Hydrochloride
Description: at the end of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: at the end of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: at the end of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injectable Solution
Description: at the of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injectable Solution
Description: at the of the procedure
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: at the end of the procedure for infiltration of trocar wounds
Study NCT02953210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: at the end of the procedure for infiltration of trocar wounds
Study NCT04322604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study NCT04322604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01040702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a single doses of 10-20 mg in each one of two visits
Study NCT01040702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sweetener pill
Description: a capsule containing a sweetener pill
Study NCT03092284 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)
Description: Direct intramyocardial injection of CSCC_ASC
Study NCT03092284 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00850889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine
Description: Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
Study NCT00850889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A gel of hyaluronic acid (concentration of 20 mg/mL)
Description: Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
Study NCT01024036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Study NCT02132845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples
Study NCT02132845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples
Study NCT02132845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: Receive target-directed therapy
Study NCT02132845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic procedure
Description: Receive standard of care therapy
Study NCT02132845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02132845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03083314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)
Study NCT03083314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMPLETE AXILLARY DISSECTION (ALND)
Study NCT03006484 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be needed.
Study NCT03945838 — intervention group
Intervention type: OTHER
Intervention: Complete Decongestion Therapy
Description: It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments.
Study NCT05024669 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gluma desensitiser
Description: Gluma desensitiser was used before restoration.
Study NCT05024669 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sheildforce Plus desensitiser
Description: Sheildforce Plus desensitiser was used before restoration.
Study NCT05024669 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telio CS desensitiser
Description: Telio CS desensitiser was used before restoration.
Study NCT04088500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specific dose on specific days
Study NCT04088500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specific dose on specific days
Study NCT01257048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol Turbuhaler
Description: 9 microgram on visit 5 single dose
Study NCT01466803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorikonazole
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Study NCT04190290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Adapted Program
Description: 3 days / week mobilisations and respiratory exercises and body image exercises
Study NCT04190290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation and Control
Description: Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
Study NCT00428558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (DAUNORUBICINE-CYTARABINE)
Description: A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Study NCT00428558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (DAUNORUBICINE-CYTARABINE)
Description: Chemotherapy induction sequential
Study NCT00284063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low back adjustment and MRI
Description: Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
Study NCT00284063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low back adjustment and MRI
Description: Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
Study NCT00284063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
Study NCT04075825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
Study NCT02089308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Test treatment : V0116 transdermal patch
Study NCT02089308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reference treatment : Nicotine transdermal patch
Study NCT01257048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol Turbuhaler
Description: 320/9 microgram twice daily during 8 weeks
Study NCT01257048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Turbuhaler
Description: 9 microgram twice daily during 8 weeks
Study NCT00806741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
Study NCT00806741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1μg/kg/min, infusion period 20 minutes
Study NCT00806741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes
Study NCT00806741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head
Study NCT04190290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation and Control
Description: Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
Study NCT01115218 — intervention group
Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: Trabeculectomy with mitomycin C
Study NCT04065893 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter ablation of ventricular arrhythmia
Description: PVC or VT ablation
Study NCT04065893 — intervention group
Intervention type: DRUG
Intervention: Intensified medical therapy
Description: Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
Study NCT02367495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCB
Description: PCB with Citrate-based excipient
Study NCT00585351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50 mg single dose injection of Ranitidine
Study NCT00585351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 50 mg single dose injection of Ranitidine
Study NCT00585351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg single dose injection of normal saline (placebo)
Study NCT00585351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg single dose injection of normal saline (placebo)
Study NCT00585351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced notification
Description: Advanced notification of study via faxed consent to local Emergency Room (ER)
Study NCT01421823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha agonist ointment
Description: 2 weeks local treatment with alpha agonist ointment
Study NCT00740961 — intervention group
Intervention type: BEHAVIORAL
Intervention: compliance monitoring
Description: Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
Study NCT00740961 — intervention group
Intervention type: DRUG
Intervention: systemic chemotherapy
Description: Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
Study NCT00740961 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
Study NCT00740961 — intervention group
Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
Study NCT00740961 — intervention group
Intervention type: OTHER
Intervention: survey administration
Description: Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
Study NCT00740961 — intervention group
Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
Study NCT00740961 — intervention group
Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
Study NCT04390984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate, Gefitinib
Description: Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940 40 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Study NCT02141763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB4940 40 mg
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous